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ABSTRACT
Objective Evaluation of the ratio of oxyhaemoglobin 
to total haemoglobin in skeletal muscle (StO2) using 
near-infrared spectroscopy may aid in the monitoring of 
patients with sepsis. This study assessed the benefits 
and risks of targeting StO
2 in adults with severe sepsis 
or septic shock.
Design A European randomised controlled trial was 
performed on two parallel groups.
Setting Five intensive care units (ICU) in France, Greece, 
Spain and Germany were used for the study.
Participants A total of 103 adults with severe sepsis 
or septic shock on ICU admission were randomised (54 
subjects in the experimental arm and 49 subjects in the 
control arm).
Interventions Haemodynamic management using an 
algorithm that was adapted from the 2004 Surviving 
Sepsis Campaign guidelines with (experimental arm) 
or without (control arm) targeting an StO
2 value greater 
than 80% at a minimum of two different sites.
Outcomes The primary outcome was a composite: 
7-day all-cause mortality or worsening of organ function, 
defined as a positive difference in Sepsis-related Organ 
Failure Assessment (SOFA) score between day 7 and 
randomisation (ie, delta SOFA >0). Secondary endpoints: 
30-day mortality, duration of mechanical ventilation and 
vasopressor therapy up to 30 days from randomisation.
Results The study ended prematurely due to lack of 
funding after enrolment of 103/190 patients. Eighteen 
patients (33.3%) in the experimental arm and 14 
(28.6%, P=0.67) in the control arm died or exhibited 
delta SOFA >0 on day 7. The mean number of days 
on mechanical ventilation was 12.2±10.6 in the 
experimental group and 7.6±7.9 in the control group 
(P=0.03). Thirty-one (57%) patients in the experimental 
arm and 14 (29%) patients in the control arm received 
red cells by day 7 (P=0.01).
Conclusion Despite the limitation related to premature 
termination, this study provides no data to support 
the routine implementation of resuscitation protocols 
incorporating StO
2 >80% at two or more muscle sites 
as a target. StO2-guided therapy may be associated with 
prolonged use of mechanical ventilation and an increased 
number of red blood cell transfusions.
Trial registration number NCT00167596; Results.
InTRODuCTIOn
Near-infrared spectroscopy (NIRS) is based 
on the capacity of different chromophores 
in tissues to absorb light in the 700–1000 nm 
wavelength range. Analysis of the light 
emitted and received provides a non-invasive 
and continuous semiquantitative calcula-
tion of the ratio of oxyhaemoglobin to total 
haemoglobin in skeletal muscle (ie, the tissue 
oxygen saturation or skeletal muscle tissue 
oxygenation). Basal StO2 values of 86%±6% 
were reported in the thenar prominence 
(Thenar-StO2) in healthy volunteers. Eval-
uation of StO2 using NIRS may aid in the 
monitoring of patients with sepsis or septic 
shock.1 2 A low StO2 value during sepsis may be 
associated with poor clinical outcomes3–6 and 
reflect altered microcirculatory perfusion.7 
StO2 values under 75% in septic patients were 
associated with poor outcomes.1 3–5 However, 
there is important overlap between patho-
logical values and the values obtained under 
normal conditions.1 The 2004 guidelines for 
the management of sepsis recommended 
early quantitative resuscitation protocolised 
care based on a set of central haemodynamic 
Strengths and limitations of this study
 ► This study is the first randomised trial of near-infra-
red spectroscopy-derived StO2-guided resuscitation 
in sepsis or septic shock.
 ► The trial was performed in five major intensive care 
units in four European countries.
 ► High standards to limit the risk of selection, such 
as consensus definition for sepsis and appropriate 
allocation concealment, and performance biases, in-
cluding strict implementation of the 2004 Surviving 
Sepsis Campaign guidelines were used.
 ► Study limitations included the lack of assessor 
blinding for the primary outcome and its premature 
termination, which reduced the power.
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targets, including mean arterial pressure (MAP), heart 
rate, urinary output, central venous pressure (CVP) and 
global indices of tissue hypoperfusion (ie, central venous 
oxygen saturation and/or lactate clearance).8 9 The 
Surviving Sepsis Campaign guidelines do not include 
recommendations for monitoring or targeting the micro-
circulation, but interventions, such as inotropes and 
blood products transfusion, may affect sepsis survival.8–11 
Some patients continue to exhibit altered microcircula-
tion, for example, low StO2 associated with poor clinical 
outcomes, despite completion of early quantitative proto-
colised care.6 Our previous pilot study evaluated the feasi-
bility of targeting the microcirculation via monitoring of 
StO2 at multiple sites in patients who completed a 6-hour 
bundle of the Surviving Sepsis Campaign.12 The present 
European, multicentre, randomised trial (the Opti-
mization of Tissue Oxygenation-StO2 in Sepsis Study) 
assessed the benefits and risks of targeting StO2 in adults 
with severe sepsis who were managed according to the 
6-hour bundle of the 2004 Surviving Sepsis Campaign. 
Our hypothesis was that StO2 evaluation would aid in 
the detection of patients who remained under-resusci-
tated after completion of early goal-directed therapy, 
and further StO2-guided haemodynamic treatment may 
improve their clinical outcomes.
MATeRIAlS AnD MeThODS
Study design
The ethics committees of the participating institutions in 
France (n=2), Greece (n=1), Spain (n=1) and Germany 
(n=1) approved the protocol for this multicentre, 
randomised, non-blinded phase II/III trial. Recruitment 
into the trial began in February 2006 and ended in May 
2009. An independent safety, efficacy and data-mon-
itoring committee reviewed the study protocol prior to 
the initiation of recruitment and periodically reviewed 
the accumulated study data. All authors contributed to 
the design of the study, recruitment of patients, and data 
collection and interpretation. The sponsor had no role 
in the design or conduct of the study, in the collection, 
management, analysis, or interpretation of the data, or 
the preparation, review, approval or submission of the 
manuscript. This trial is registered at  ClinicalTrials. gov 
under NCT00167596.
Patients
Patients with suspected or confirmed sources of infection 
were considered for enrolment in this study if they were 
18 years of age or older, admitted to the intensive care 
unit (ICU), met two or more of the Systemic Immune 
Response Syndrome criteria13 and exhibited at least 
one of the following signs of tissue hypoperfusion: (1) a 
systolic blood pressure of 90 mm Hg or less; (2) arterial 
lactate level of 4 mmol/L or more; (3) mottled skin; (4) 
urine output below 30 mL/hour for at least 1 hour; and 
(5) altered mental status. The time window for inclusion 
was less than 8 hours from the onset of the first sign of 
hypoperfusion. Patients younger than 18 years, pregnant 
women, brain-dead patients and patients who decided 
to withhold or withdraw from life-supporting treatments 
were not eligible.
Randomisation (1:1 ratio) was stratified according to 
the study centre and balanced by blocks of 4 using a 
computerised random number generator list provided 
by an independent statistician. Sequentially numbered, 
sealed and opaque envelopes were used. Each enve-
lope was assigned to a patient and opened only after 
the investigator wrote the patient’s information on it 
and faxed the signed inclusion sheet with the patient’s 
randomisation details to the coordinating centre. This 
procedure allowed for the monitoring of treatment 
allocation to unique patients in an appropriate order.
Interventions
Subjects were managed using an algorithm that was 
adapted from the 2004 Surviving Sepsis Campaign guide-
lines.14 Briefly, patients received 500 mL of crystalloids 
or colloids every 30 min until their CVP was between 8 
and 12 mm Hg. Vasopressor therapy (norepinephrine 
or epinephrine) was initiated if the MAP remained 
lower than 65 mm Hg, using titration until an MAP 
of 65–80 mm Hg was reached. Packed red blood cells 
were transfused if the central venous oxygen saturation 
(ScvO2) was lower than 70% and haematocrit levels were 
lower than 30%. Dobutamine was initiated at a dose of 
2.5 µg/kg/min if the ScvO2 was lower than 70% and the 
haematocrit levels were higher than 30%. Dobutamine 
was titrated in incremental steps of 2.5 µg/kg/min every 
30 min until the ScvO2 level was 70% or greater without 
exceeding an infusion rate of 20 µg/kg/min. The dobuta-
mine infusion rate was kept constant as soon as all of the 
haemodynamic goals were achieved or decreased when-
ever the heart rate exceeded 120/min. The CVP, MAP 
and ScvO2 were optimised in the StO2 arm, and the inter-
ventions (figure 1) targeted StO2 values of 80% or greater 
in at least two muscular sites in the thenar, masseter and 
deltoid areas.
ScvO2 and StO2 recordings
All patients had an arterial line placed in the radial 
or femoral artery and a catheter in the superior vena 
cava. The ScvO2 and StO2 levels were recorded at base-
line (H0) and at H2, H4, H6 and H24 following rando-
misation. StO2 was recorded using an InSpectra Tissue 
Spectrometer (InSpectra 650 StO2 Tissue Oxygenation 
Monitor, Hutchinson Technology, MN, USA) and 
25 mm probes placed over the left thenar eminence 
(Thenar-StO2), left masseter muscle (Masseter-StO2) 
and left deltoid muscle (Deltoid-StO2) as described 
by Colin et al.3 Measurements of the Thenar-StO2 ipsi-
lateral to a radial arterial line were collected. The 
StO2 values were sequentially collected after 2 min of 
stable recording in the masseter, deltoid and thenar 
areas. Calibration of the spectrometer was performed 
once before monitoring as recommended by the 
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manufacturer. Adhesive shields were kept in place 
throughout the duration of the experiments. The 
StO2 was recorded in the control group and masked 
throughout the study period to the investigators and 
medical and nursing staff members.
Data collection and follow-up
The patients’ prior locations (ie, community, hospital or 
long-term care facility), Knaus categorisation of health 
status,15 McCabe class,16 severity of illness as assessed 
by vital signs, Simplified Acute Physiology Score II,17 
Sepsis-related Organ Failure Assessment (SOFA) 
score,18 type and dose of any intervention, routine 
laboratory data, arterial blood lactates and cultures of 
samples collected at any suspected site of infection were 
recorded on admission.
The vital status of the patients was followed up to 
30 days from randomisation. The type and dose of 
any intervention, ScvO2, and StO2 at H0, H2, H4, H6 
and H24 were systematically recorded during the first 
24 hours after randomisation. The SOFA score was 
recorded each morning from randomisation to day 7 
of the study.
Figure 1 Haemodynamic treatment algorithm. CVP, central venous pressure; Ht, haematocrit; MBP, mean blood pressure. 
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endpoints
The primary outcome was a composite endpoint of 
all-cause mortality on day 7 and deterioration in organ 
function as defined by a positive difference in the 
SOFA score between study day 7 and baseline (ie, delta 
SOFA >0).
The secondary endpoints included 30-day all-cause 
mortality, duration of mechanical ventilation and the 
use of vasopressors within 30 days after randomisation. 
Outcomes were assessed in a non-blinded manner.
Statistical analysis
Sample size
A total of 95 patients must be included in each arm to 
achieve a statistical power of 80%, considering that an 
absolute 20% difference in the main criterion would 
be clinically significant and the main criterion would 
be reached in 50% of the patients in the control group. 
However, the study ended after inclusion of 54 patients 
in the experimental group and 49 patients in the control 
group, which reduced the study power. The corre-
sponding power to detect a 20% absolute difference if the 
main criterion was reached in 50% of the patients in the 
control group was only 54%.
Descriptive statistics
Continuous variables are reported as the means plus or 
minus SD or medians and IQR in cases of non-normality 
in variable distribution. Categorical variables are reported 
as numbers and percentages.
Comparative analyses
We performed intent-to-treat analysis after completion of 
the last follow-up of the last recruited patients. We did 
not plan interim analyses. We did not plan formal statis-
tical comparisons of baseline characteristics because of 
the randomisation of treatment allocation. The primary 
outcome (composite endpoint of all-cause mortality on 
day 7 and deterioration in organ function as defined by 
a delta SOFA >0) was compared between groups by χ2 
tests, and relative risk and absolute difference with 95% 
CIs were computed. Comparisons of secondary outcomes 
(duration of treatment with vasopressors, duration of 
mechanical ventilation and mortality on day 30) were 
performed using χ2 tests, and relative risks with 95% CIs 
were computed. Survival curves until day 30 were created 
using the Kaplan-Meier method and compared using 
the log-rank test. We also performed post hoc statistical 
analyses to compute univariate and multivariate ORs of 
mechanical ventilation on day 7. All tests were two sided, 




The sponsor of this study withdrew support for the trial 
in May 2009 as a consequence of the global economic 
crisis. The trial was stopped as a result of the cessation of 
funding. A total of 103 patients (54% of the 190 planned) 
were enrolled at the study termination.
A total of 555 patients were screened for enrolment 
in this study from February 2006 to May 2009. A total 
of 103 of the 143 eligible patients, or their next of kin, 
provided written informed consent. Fifty-four patients 
were randomly assigned to the experimental arm, and 
49 patients were assigned to the control arm (figure 2). 
Patient characteristics and demographics of the two 
groups were well matched at baseline (table 1). The lungs 
were the most common source of infection (52.5%), and 
16% of the patients exhibited positive blood cultures. 
Eighty-six per cent of the patients in the StO2 group and 
85% in the control group were on mechanical ventilation 
at inclusion.
Resuscitation endpoints
Only 27 (26%) patients, 15 in the experimental arm and 
12 in the control arm, exhibited ScvO2 values below 70% 
at baseline (table 2). In contrast, 67 (65%) patients, 32 in 
the experimental arm and 35 in the control arm, exhib-
ited StO2 values less than 80% at two or more muscular 
sites. No significant differences between the two study 
groups were observed in any of the haemodynamic vari-
ables or lactate levels during the first 6 hours after rando-
misation (table 2). The interventions delivered to the 
patients in the experimental arm did not produce the 
intended effect on StO2, with almost one-fourth of the 
patients unable to achieve the target of StO2 >80% at ≥2 
sites (table 2).
Primary endpoint
There were 18 (33.3%) patients who died or had a delta 
SOFA >0 in the experimental arm on day 7 compared with 
14 (28.6%) patients in the control arm (absolute differ-
ence 4.8%; 95% CI −0.131 to 0.226; P=0.67) (table 3). 
There were nine (16.7%) deaths in the experimental arm 
and nine (18.4%) deaths in the control arm (absolute 
difference: 17%; 95% CI −0.13 to 0.17; P=0.69).
Secondary endpoints
There were 32 (31.1%) deaths at study day 30, 17 (31.5%) 
in the experimental arm and 15 (30.6%) in the control 
arm (P=0.90) (table 3 and figure 3). There were no 
significant differences in the time on vasopressor therapy 
between groups (5.8±13.5 days in the experimental group 
vs 4.1±5.8 days in the control group, P=0.40). Thirty-one 
(57%) patients in the experimental arm and 14 (29%) 
in the control arm received red cells by day 7 (P=0.01, 
table 3). There was a trend towards higher doses of 
dobutamine in the experimental group at day 1 (P=0.08, 
table 3). The mean number of days on mechanical ventila-
tion up to 30 days was 12.2±10.6 days in the experimental 
group and 7.6±7.9 days in the control group (P=0.03) 
(online supplementary figure 1). Thirty-six (66.7%) and 
17 (35.5%) patients were on mechanical ventilation in 
the experimental and control groups, respectively, on 
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day 7 (P<0.01, OR 3.3, 95% CI 1.2 to 8.7). This difference 
remained significant after adjustments for age and red 
cells transfusion (OR 2.9, 95% CI 1.1 to 8.1) There was 
no significant difference between groups for CVP, systolic 
blood pressure or heart rate at H6 (table 2).
DISCuSSIOn
This trial did not find any evidence for a benefit in survival 
or organ function from an NIRS-derived StO2-guided 
early goal-directed therapy. There was some evidence that 
the experimental algorithm of resuscitation was associ-
ated with prolonged mechanical ventilation, more blood 
transfusion and more use of inotropes.
The trial was terminated after the enrolment of 103 
patients because of cessation in financial support. This 
decision was made because the 2009 global economic 
crisis strongly affected the trial sponsor, Hutchinson 
Technology. Thereafter, it was not possible to obtain the 
appropriate probes for StO2 monitoring, and the clinical 
research personnel who assisted with data management 
were not available. We obtained access to the database 
in March 2010, and the final statistical report was avail-
able before the end of 2011. Thereafter, the study chair 
(DA) worked for the French government as chief coun-
sellor for the Minister of Health from May 2012 to May 
2017, and he could not publish any paper in partnership 
with health product companies. The direction of the 
point estimate for the primary outcome did not favour 
the experimental intervention, and there was a strong 
indication for harm in the analysis of the secondary 
outcomes, despite the premature termination of the 
trial. Trials stopped prematurely for efficacy may result 
in an overestimation of the effects of an experimental 
intervention,19 but this trial was stopped as a conse-
quence of the global economic crisis and not because of 
treatment efficacy.
This study was the first multicentre randomised trial of 
NIRS-derived StO2-guided resuscitation in sepsis or septic 
shock. We found no evidence to support the addition of 
muscle StO2 as a surrogate of microcirculation evalua-
tion in the early phase of haemodynamic management of 
patients with sepsis.8 There was no gold standard for micro-
circulation available to compare our StO2-guided strategy. 
We evaluated a clinical algorithm that included targeting 
StO2 above 80% in at least two different sites. Therefore, 
the present study did not evaluate the performance of 
StO2 for the diagnosis of microcirculatory dysfunction, 
but it evaluated the downstream consequences of the use 
of StO2 on clinical outcomes. The experimental strategy 
of targeting muscle StO2 produced no survival benefit 
and no evidence in favour of the prevention or hastening 
of the resolution of organ dysfunction.
Figure 2 Study flow diagram.
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The experimental algorithm in this trial was similar to 
previously described algorithms for early goal-directed 
therapy.20 The experimental algorithm was associated 
with prolonged mechanical ventilation and a greater 
number of patients requiring blood product transfu-
sions and dobutamine infusion. Both interventions may 
improve the microcirculatory function of patients who 
are critically ill with sepsis,10 11 but the resuscitation algo-
rithm failed to normalise muscle StO2 in most patients. 
However, the aggressive use of dobutamine21 and red cell 
transfusion22 is also associated with poor outcomes in 
ICU patients. The benefits of targeting muscle StO2 via 
interventions other than dobutamine and blood products 
deserve further investigation. The concept of early goal-di-
rected therapy was challenged in three large sepsis 
trials.23–25 The results reflect that the global management 
of patients has substantially changed since the landmark 
study of Rivers et al.20 However, the treatment strategies 
tested in these trials did not include microcirculation as 
a target. Therefore, the recent challenge of early goal-di-
rected therapy may not affect the results of our study.
The inclusion of muscle StO2 targets in the quantita-
tive resuscitation protocolised care was associated with 
prolonged mechanical ventilation, which may have at 
least partially resulted from increased blood transfu-
sions.22 Notably, the weaning of patients from mechanical 
ventilation followed current guidelines in both trial arms. 
This result encourages the monitoring of ventilation 
length in further studies.
We chose to target skeletal muscle StO2 values of 80% 
or greater because this cut-off corresponded to the lower 
limit of the 95% CI in healthy volunteers and discrimi-
nated between sepsis survivors and non-survivors.26
We used the commonly accepted NIRS technology 
to measure StO2
5 6 and recorded StO2 from the three 
different areas to obtain a broader evaluation of tissue 
oxygenation.12 27 We used steady-state StO2 values rather 
than values obtained during vascular occlusion tests. The 
assessment of dynamic changes in StO2 during and imme-
diately after limb ischaemia may be more sensitive than 
steady-state StO2 values to detect the extent of microcir-
culation dysfunction during sepsis.28 29 However, vascular 
occlusion test results may depend on the probe and site 
of measurement,30 and these measurements are cumber-
some and inconvenient for serial assessments at very short 
intervals.31 32 The vascular occlusion test cannot be used 
to assess muscle StO2 at multiple sites.
A major objective of the initial resuscitation of patients 
with sepsis is to prevent the deterioration of organ func-
tion. The SOFA score is an effective method to describe 
organ dysfunction/failure in patients who are critically ill. 
Regular, repeated scoring enables effective monitoring of 
patient condition and disease development, and it may 
enable comparisons between patients who would benefit 
in clinical trials.33
The delta SOFA score may be used to quantify the 
degree of dysfunction/failure already present on ICU 
admission, the degree of dysfunction/failure that appears 
during the ICU stay and the cumulative insult suffered by 
the patient. These properties make it a good instrument 
in the evaluation of organ dysfunction/failure.34
Patients who exhibit a 1-point increase in SOFA score 
during the first days of ICU had death rates >50%, which 
is markedly higher than patients in whom the SOFA 
score decreased by 1 point (mortality 23%) or remained 
unchanged (mortality 31%).35
The overall recruitment rate of this study was low, 
primarily because most patients entered the ICU beyond 
the 8-hour time window from sepsis onset. This trial found 
that approximately two-thirds of patients with sepsis/septic 
shock exhibited baseline StO2 levels <80% at two sites, and 






Expected number of patients 95 95
Actual number of patients 54 49
Age (year) 65.6±16 60.8±18
Sex (%)
  Female 33.3 32.7 
  Male 66.6 67.3 
BMI (kg/m²) 25±3 24±4
McCabe score (%)
  No underlying or non-fatal 
disease
66.6 71.4
  Fatal disease (<5 years) 25.9 26.5
  Rapidly fatal disease (<1 year) 5.5 0
Knaus
  No limitation 44.4 40.8
  Moderate activity limitation 25.9 28.6
  Severe activity limitation 16.7 26.5
  Bedridden patient 13.0 4.1
SAPSII 48±23 51±18
SOFA on ICU admission 10±4 9±4
Source of infection (%)
  Lung 51.9 53.1
  Abdominal 20.4 14.3
  Urogenital 14.8 18.3
Sepsis type (%)
  Nosocomial 35.2 42.9
  Community acquired 64.8 57.1
Positive blood culture (%) 14.8 16.3
Corticosteroids, n (%) 31 (57) 26 (53)
Activated protein C treatment, 
n (%)
8 (15) 3 (6)
The plus-minus values are the means±SDs.
BMI, body mass index; ICU, intensive care unit; SAPSII, Simplified 
Acute Physiology Score II; SOFA, Sepsis-related Organ Failure 
Assessment. 
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Table 2 Vital signs, resuscitation goals
Variable and treatment group
Expected number 
of patients
Actual number of 
patients
Baseline Hours after start of therapy
0 2 4 6
Systolic blood pressure (mm Hg) 
  Experimental arm 95 54 112±26 118±27 120±23 120±22
  Control arm 95 49 115±29 120±24 116±23 117±23
  P value 0.7 0.6 0.2 0.3
Central venous pressure (mm Hg) 
  Experimental arm 95 54 10±5 11±4 11±4 11±4
  Control arm 95 49 9±4 10±4 10±4 10±4 
  P value 0.25 0.2 0.2 0.2
Heart rate (beats/min)
  Experimental arm 95 54 105±25 101±23 101±24 98±24 
  Control arm 95 49 103±24 99±24 101±24 100±24 
  P value 0.6 0.7 1 0.6
Lactates (mmol/L) 
  Experimental arm 95 54 6.6±10 6.4±9.6 7.3±11.7 7.6±12.9
  Control arm 95 49 6.3±9.0 6.1±8.5 6.3±8.8 6.8±9.2 
  P value 0.9 0.9 0.6 0.7 
PaO2/FiO2 (mm Hg)
  Experimental arm 95 54 180±105 193±114 199±105 207±112 
  Control arm 95 49 196±140 193±127 193±124 194±113 
  P value 0.6 1 0.9 0.5 
ScvO2 (%) 
  Experimental arm 95 54 74.5±11 76±12 77±12 77±11 
  Control arm 95 49 75±11 74±13 75±11 74±10 
  P value 0.6 0.4 0.5 0.2
ScvO2 <70% (%) 
  Experimental arm 95 54 30 21 22 24
  Control arm 95 49 27 26 22 22
  P value 0.8 1 0.6 0.6
Masseter-StO2 (%) 
  Experimental arm 95 54 70±19 72±18 73±18 71±20
  Control arm 95 49 68±22 67±24 66±26 62±28 
  P value 0.7 0.3 0.15 0.09 
Masseter-StO2 <80% (%)
  Experimental arm 95 54 62 59 51 63 
  Control arm 95 49 57 63 65 74 
  P value 0.7 0.4 0.3 0.3 
Deltoid-StO2 (%) 
  Experimental arm 95 54 58±25 59±26 60±25 57±26
  Control arm 95 49 60±23 59±24 59±25 55±27 
  P value 0.7 0.9 0.8 0.7 
Deltoid-StO2 <80% (%) 
  Experimental arm 95 54 70 69 71 79
  Control arm 95 49 77 72 74 79 
  P value 0.4 0.8 0.7 0.9 
Continued
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the vast majority exhibited ScvO2 over 70%. These findings 
confirm that abnormal StO2 may be a common feature in 
sepsis/septic shock. This trial found that the inclusion of 
StO2 >80% as a target in the algorithm for early goal-di-
rected therapy likely provided no value in clinical outcomes. 
However, these findings do not exclude a potential benefit of 
targeting StO2 in a different protocol using different cut-off 
values or treatment strategies. These findings do not exclude 
a potential benefit of targeting other surrogates of microcir-
culation. The Surviving Sepsis Campaign guidelines were 
updated twice,8 9 and the definition of sepsis was updated 
once,36 since our trial was performed. The 2016 updated 
guidelines still include no statement about targeting the 
microcirculation in sepsis. There are several techniques to 
Variable and treatment group
Expected number 
of patients
Actual number of 
patients
Baseline Hours after start of therapy
0 2 4 6
Thenar-StO2 (%) 
  Experimental arm 95 54 83±10 83±11 81±16 81±16
  Control arm 95 49 81±10 79±9 77±14 78±13 
  P value 0.3 0.11 0.17 0.25 
Thenar-StO2 <80% (%) 
  Experimental arm 95 54 31 32 26 31
  Control arm 95 49 37 43 43 54 
  P value 0.5 0.4 0.08 0.02 
StO2 >80% over two sites (%) 
  Experimental arm 95 54 28 39 40 34 
  Control arm 95 49 29 33 36 23
  P value 0.7 0.6 0.5 0.2
Table 2 Continued 
Table 3 Study outcomes
Outcome Experimental arm Control arm Incremental effect (95% CI) P value
Expected number of patients 95 95
Actual number of patients 54 49
Primary outcome: death at day 7 or DSOFA >0, 
n (%)
18 (33.3) 14 (28.6) 0.67
  Relative risk 1.17 (0.58 to 2.34) 0.67
  Absolute risk reduction −4.7 (−22.6 to 13.1)
  Unadjusted OR 1.25 (0.54 to 2.89) 0.64
  Adjusted OR (on age and gender) 1.22 (0.52 to 2.87) 0.64
Secondary outcomes
  Death at day 30, n (%) 17 (31.5) 15 (30.6) 1.04 (0.45 to 2.4) 0.9
  Time on vasopressor up to 30 days, days (SD) 5.8 (13.5) 4.1 (5.8) 1.7 (−2.3 to 5.7) 0.4
  Time on advanced respiratory support up to 
30 days, days (SD)
12.2 (10.6) 7.6 (7.9) 4.6 (0.97 to 8.2) 0.03
  Participants infused with dobutamine up to 
the sixth hour, %
75 70 1.48 (0.6 to 3.8)* 0.5
  Mean dobutamine dose in milligrams per hour 
during day 1, mg/hour (SD)
11.5 (21.3) 5.9 (11.5) 5.6 (−1.2 to 12.4) 0.08† 
  Participants who received a transfusion of red 
cells up to day 7, %
57 29 3.3 (1.5 to 7.7)* 0.01
For one patient without a day 7 SOFA score, the last known SOFA score value (day 6 SOFA score) was used for the calculation of the 
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measure/monitor microcirculation, but no trials have inves-
tigated their usefulness in guiding patient resuscitation.37
COnCluSIOnS
The present study ended prematurely due to lack of funding. 
Nevertheless, the current findings provide no evidence for 
any potential benefit from targeting muscle StO2 in addition 
to CVP, MAP and ScvO2. The targeting of muscle StO2 for 
early goal-directed therapy failed to significantly increase 
muscle StO2 in most patients, and it was associated with 
prolonged mechanical ventilation, increased blood transfu-
sions and increased doses of dobutamine.
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